The US Food and Drug Administration sees proactive surveillance of complex generics as a chance to avoid patient rejection of first generics in addition to monitor for any potential safety problems.
Adverse Events For Generic Of GSK's Advair Diskus On US FDA’s Radar
As patients log device complaints for Mylan’s Advair Diskus generic Wixela Inhub, the agency is assessing whether additional reminders about the products’ differences are needed.
